Search
for
Sort by
Research 121–150 of 1000+
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- CURRENT UNDERSTANDING OF VITILIGO: A COMPREHENSIVE LITERATURE REVIEW
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Current and future pharmacotherapy for alopecia areata
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Psychophysiological Mechanisms of Stress Impact on Hair Loss Processes
- New drugs under investigation for the treatment of alopecias
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
- Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- The Changing Landscape of Alopecia Areata: The Translational Landscape
- Efficacy of tofacitinib in pediatric alopecia universalis
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1